Home › Research › Drug development
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Natalia García-Casares, Guillermo González-González, Carlos de la Cruz-Cosme, Francisco J Garzón-Maldonado, Carmen de Rojas-Leal, María J Ariza, Manuel Narváez, Miguel Ángel Barbancho et al.. Reviews in endocrine & metabolic disorders, 2023-05-26
Topic: Gut, metabolism and diet
Plain-language summary
Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy. We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy. Semaglutide subcutaneous and dulaglutide reduced stroke cases. Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events. Exenatide, dulaglutide and liraglutide improved general cognition but no significant effect on diabetic peripheral neuropathy has been reported with GLP-1 RAs. GLP-1 RAs are promising drugs that seem to be useful in the reduction of some neurological complications of diabetes. However, more studies are needed.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
García-Casares, N., González-González, G., de la Cruz-Cosme, C., Garzón-Maldonado, F. J., de Rojas-Leal, C., Ariza, M. J., et al. (2023). Effects of GLP-1 receptor agonists on neurological complications of diabetes. Reviews in endocrine & metabolic disorders. https://doi.org/10.1007/s11154-023-09807-3
Vancouver
García-Casares N, González-González G, de la Cruz-Cosme C, Garzón-Maldonado FJ, de Rojas-Leal C, Ariza MJ, et al. Effects of GLP-1 receptor agonists on neurological complications of diabetes. Reviews in endocrine & metabolic disorders. 2023. doi:10.1007/s11154-023-09807-3. PMID: 37231200.
BibTeX
@article{garciacasares2023-37231200,
author = {García-Casares, Natalia and González-González, Guillermo and de la Cruz-Cosme, Carlos and Garzón-Maldonado, Francisco J and de Rojas-Leal, Carmen and Ariza, María J and Narváez, Manuel and Barbancho, Miguel Ángel and others},
title = {{Effects of GLP-1 receptor agonists on neurological complications of diabetes}},
journal = {Reviews in endocrine \& metabolic disorders},
year = {2023},
doi = {10.1007/s11154-023-09807-3},
pmid = {37231200},
url = {https://doi.org/10.1007/s11154-023-09807-3}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy.
- We found a total of 19 studies: 8 studies include stroke or major cardiovascular events, 7 involve cognitive impairment and 4 include peripheral neuropathy.
- Exenatide, dulaglutide and liraglutide improved general cognition but no significant effect on diabetic peripheral neuropathy has been reported with GLP-1 RAs.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designsystematic review
- Participants19
- Evidence strengthHigh
How this study scored 77/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 43 of the 56 points we could judge it on, which is 77 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Reviews in endocrine & metabolic disorders) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 19 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37231200) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 43 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 43 of the 56 points we could judge it on is 77 out of 100. |
| Total | 77 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “peptide-1”
285 studies in the library carry the topic tag “peptide-1”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 285 tagged studies.